<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227591</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02976</org_study_id>
    <secondary_id>NCI-2012-02976</secondary_id>
    <secondary_id>ECOG-E4903</secondary_id>
    <secondary_id>E4903</secondary_id>
    <secondary_id>E4903</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT00227591</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Prednisone in Treating Patients With Myelofibrosis</brief_title>
  <official_title>A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving lenalidomide together with prednisone works
      in treating patients with myelofibrosis. Lenalidomide may stop the growth of myelofibrosis by
      blocking blood flow to the cancer. It may also stimulate the immune system in different ways
      and stop cancer cells from growing. Drugs used in chemotherapy, such as prednisone, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Giving lenalidomide together with prednisone may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the rate of complete or partial remission from treatment with a combination of
      lenalidomide and prednisone in patients with myelofibrosis with myeloid metaplasia.

      SECONDARY OBJECTIVES:

      I. To examine drug toxicity. II. To examine duration of response. III. To examine the effect
      of treatment on bone marrow fibrosis, angiogenesis, and cytogenetics.

      OUTLINE:

      For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once
      daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28
      and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27.
      Patients with stable or responding disease after course 3 receive oral lenalidomide alone
      once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses
      in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 1 year and then
      every 6 months for up to 5 years from study entry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Assessed at the end of cycle 3</time_frame>
    <description>Response was evaluated for Anemia and Spleen:
Major anemia response: hemoglobin increase to within normal limits in the absence of transfusion. Minor anemia response: hemoglobin improvement of at least 2 grams per deciliter independent of transfusion support, or achievement of transfusion independence in transfusion-dependent patients. Major spleen response: normalization of spleen size to the range of 12-14 centimeters by ultrasound. Minor spleen response: a 50% or more decrease in excess spleen size by ultrasound. Complete remission (CR): complete resolution of disease-related symptoms, splenomegaly, normalization of peripheral blood count, white cell differential and smear, and normalization of bone marrow histology. Partial remission (PR): a major or minor response in anemia or splenomegaly. Overall Response (OR)=CR + PR, assessed among eligible, treated patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (lenalidomide, prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Given orally (PO)</description>
    <arm_group_label>Treatment (lenalidomide, prednisone)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>IMiD-1</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide, prednisone)</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (lenalidomide, prednisone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be diagnosed with myelofibrosis with myeloid metaplasia (MMM); agnogenic
             myeloid metaplasia, post-polycythemic myeloid metaplasia, or post-thrombocythemic
             myeloid metaplasia are included

               -  NOTE: Diagnosis must be confirmed by central pathology review; diagnostic samples
                  must be submitted; patient may register and begin treatment based on the local
                  pathology review. If the central review does not confirm patient's eligibility to
                  participate in the trial, protocol treatment must be discontinued

          -  Patient must have discontinued chemotherapy (hydroxyurea, alpha interferon,
             anagrelide, other myelosuppressive agents, thalidomide, or any other experimental
             therapy) as well as growth factors and systemic use of corticosteroids &gt;= 28 days
             prior to starting study drug

               -  All non-hematologic toxicity must be resolved to =&lt; grade 1

          -  Patient must be lenalidomide-na√Øve (never treated with lenalidomide)

          -  ECOG performance status (PS) of 0, 1, or 2 at study entry

          -  Hemoglobin level =&lt; 10 g/dL or transfusion-dependent

          -  Absolute neutrophil count &gt;= 1,000 uL

          -  Platelet count &gt;= 100,000 uL

          -  Serum creatinine =&lt; 2.0 mg/dL

          -  Total bilirubin =&lt; 2.0 mg/dL (if elevated; direct bilirubin =&lt; 2.0 mg/dL)

          -  AST (SGOT) =&lt; 3 x ULN unless attributed to hepatic extramedullary hematopoiesis

          -  Women must not be pregnant or breastfeeding because this study involves an
             investigational agent whose genotoxic, mutagenic, and teratogenetic effects on the
             developing fetus and newborn are unknown; women of childbearing potential who are
             sexually active, must use 2 accepted methods of birth control at the same time for 4
             weeks prior to lenalidomide treatment, during lenalidomide treatment, and up to 4
             weeks after lenalidomide treatment is finished; sexually active males must use a latex
             condom for contraception during the study and up to 4 weeks after treatment with
             lenalidomide has ended

               -  All females of childbearing potential must have a blood test 10-14 days prior to
                  the start of lenalidomide treatment to rule out pregnancy; another blood test to
                  rule out pregnancy must be done 24 hours prior to the start of treatment with
                  lenalidomide

          -  Patient must not have any condition, including the presence of laboratory
             abnormalities, which, based on the physician's opinion, places the patient at
             unacceptable risk if he/she were to participate in the study or confounds the ability
             to interpret data from the study

          -  Patient must not have any known hypersensitivity to thalidomide or lenalidomide

          -  Patient must not have any known positive status for HIV or infectious hepatitis type
             A, B or C

          -  Patient must not have any other active malignancy

               -  NOTE: SWOG patients are strongly encouraged to be registered on SWOG-9007
                  (&quot;Cytogenetic Studies in Leukemia Patients&quot;); SWOG institutions registering
                  patients to SWOG-9007 should follow the instructions for specimen submission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayalew Tefferi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <results_first_submitted>October 11, 2012</results_first_submitted>
  <results_first_submitted_qc>July 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2013</results_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study accrued 48 cases between December 2, 2005 and March 9, 2007. Per two-stage design, the study was suspended on May 31, 2006 for a toxicity and response analysis. Since more than 4 patients achieved a response, the study was reactivated on December 5, 2006. Accrual continued to a total of 48 patients and terminated on March 9, 2007.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>Lenalidomide 10 mg/day plus prednisone X 28 days X 3 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48">48 pts registered to the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Began Treatment</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>Lenalidomide 10 mg/day plus prednisone X 28 days X 3 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Response was evaluated for Anemia and Spleen:
Major anemia response: hemoglobin increase to within normal limits in the absence of transfusion. Minor anemia response: hemoglobin improvement of at least 2 grams per deciliter independent of transfusion support, or achievement of transfusion independence in transfusion-dependent patients. Major spleen response: normalization of spleen size to the range of 12-14 centimeters by ultrasound. Minor spleen response: a 50% or more decrease in excess spleen size by ultrasound. Complete remission (CR): complete resolution of disease-related symptoms, splenomegaly, normalization of peripheral blood count, white cell differential and smear, and normalization of bone marrow histology. Partial remission (PR): a major or minor response in anemia or splenomegaly. Overall Response (OR)=CR + PR, assessed among eligible, treated patients.</description>
        <time_frame>Assessed at the end of cycle 3</time_frame>
        <population>6 ineligible patients were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>Lenalidomide 10 mg/day plus prednisone X 28 days X 3 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Response was evaluated for Anemia and Spleen:
Major anemia response: hemoglobin increase to within normal limits in the absence of transfusion. Minor anemia response: hemoglobin improvement of at least 2 grams per deciliter independent of transfusion support, or achievement of transfusion independence in transfusion-dependent patients. Major spleen response: normalization of spleen size to the range of 12-14 centimeters by ultrasound. Minor spleen response: a 50% or more decrease in excess spleen size by ultrasound. Complete remission (CR): complete resolution of disease-related symptoms, splenomegaly, normalization of peripheral blood count, white cell differential and smear, and normalization of bone marrow histology. Partial remission (PR): a major or minor response in anemia or splenomegaly. Overall Response (OR)=CR + PR, assessed among eligible, treated patients.</description>
          <population>6 ineligible patients were excluded from the analysis.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.14" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment (up to 6 months) and for 30 days after the end of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>Lenalidomide 10 mg/day plus prednisone X 28 days X 3 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Heart block sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdomen pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea without prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with gr3-4 neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea witout prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspepsia muco</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity limb pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

